LIPOCINE INC (LPCN) Stock Fundamental Analysis

NASDAQ:LPCN • US53630X2036

8.66 USD
-0.01 (-0.12%)
At close: Feb 13, 2026
8.49 USD
-0.17 (-1.96%)
After Hours: 2/13/2026, 8:22:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

LPCN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. LPCN has a great financial health rating, but its profitability evaluates not so good. LPCN shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year LPCN was profitable.
  • In the past year LPCN has reported a negative cash flow from operations.
  • LPCN had negative earnings in 4 of the past 5 years.
  • In the past 5 years LPCN always reported negative operating cash flow.
LPCN Yearly Net Income VS EBIT VS OCF VS FCFLPCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

  • The Return On Assets of LPCN (-34.06%) is comparable to the rest of the industry.
  • With a Return On Equity value of -38.72%, LPCN perfoms like the industry average, outperforming 58.12% of the companies in the same industry.
Industry RankSector Rank
ROA -34.06%
ROE -38.72%
ROIC N/A
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
LPCN Yearly ROA, ROE, ROICLPCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LPCN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LPCN Yearly Profit, Operating, Gross MarginsLPCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • LPCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LPCN has more shares outstanding
  • LPCN has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LPCN Yearly Shares OutstandingLPCN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
LPCN Yearly Total Debt VS Total AssetsLPCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • LPCN has an Altman-Z score of -3.08. This is a bad value and indicates that LPCN is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of LPCN (-3.08) is comparable to the rest of the industry.
  • There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.08
ROIC/WACCN/A
WACC9.22%
LPCN Yearly LT Debt VS Equity VS FCFLPCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • A Current Ratio of 8.25 indicates that LPCN has no problem at all paying its short term obligations.
  • LPCN has a Current ratio of 8.25. This is in the better half of the industry: LPCN outperforms 74.35% of its industry peers.
  • LPCN has a Quick Ratio of 8.25. This indicates that LPCN is financially healthy and has no problem in meeting its short term obligations.
  • LPCN has a better Quick ratio (8.25) than 74.87% of its industry peers.
Industry RankSector Rank
Current Ratio 8.25
Quick Ratio 8.25
LPCN Yearly Current Assets VS Current LiabilitesLPCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • LPCN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 168.92%, which is quite impressive.
  • Measured over the past years, LPCN shows a very strong growth in Earnings Per Share. The EPS has been growing by 21.91% on average per year.
  • Looking at the last year, LPCN shows a very negative growth in Revenue. The Revenue has decreased by -45.44% in the last year.
  • Measured over the past years, LPCN shows a very strong growth in Revenue. The Revenue has been growing by 133.89% on average per year.
EPS 1Y (TTM)168.92%
EPS 3Y21.91%
EPS 5YN/A
EPS Q2Q%-43.9%
Revenue 1Y (TTM)-45.44%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -39.17% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 37.92% on average over the next years. This is a very strong growth
EPS Next Y-230.15%
EPS Next 2Y-78.85%
EPS Next 3Y-39.17%
EPS Next 5YN/A
Revenue Next Year-90.97%
Revenue Next 2Y-75.39%
Revenue Next 3Y-52.73%
Revenue Next 5Y37.92%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
LPCN Yearly Revenue VS EstimatesLPCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 20M 40M 60M 80M
LPCN Yearly EPS VS EstimatesLPCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • LPCN is valuated correctly with a Price/Earnings ratio of 16.98.
  • Based on the Price/Earnings ratio, LPCN is valued cheaper than 86.39% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of LPCN to the average of the S&P500 Index (27.19), we can say LPCN is valued slightly cheaper.
  • The Forward Price/Earnings Ratio is negative for LPCN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 16.98
Fwd PE N/A
LPCN Price Earnings VS Forward Price EarningsLPCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LPCN Per share dataLPCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A cheap valuation may be justified as LPCN's earnings are expected to decrease with -39.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-78.85%
EPS Next 3Y-39.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for LPCN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LIPOCINE INC

NASDAQ:LPCN (2/13/2026, 8:22:04 PM)

After market: 8.49 -0.17 (-1.96%)

8.66

-0.01 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-11
Inst Owners18.59%
Inst Owner Change1.5%
Ins Owners2.84%
Ins Owner Change0%
Market Cap48.06M
Revenue(TTM)4.32M
Net Income(TTM)-5.48M
Analysts82.5
Price Target11.09 (28.06%)
Short Float %2.38%
Short Ratio0.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.8%
Min EPS beat(2)-7.12%
Max EPS beat(2)-0.49%
EPS beat(4)2
Avg EPS beat(4)137.56%
Min EPS beat(4)-7.12%
Max EPS beat(4)555.88%
EPS beat(8)6
Avg EPS beat(8)100.41%
EPS beat(12)7
Avg EPS beat(12)53.04%
EPS beat(16)10
Avg EPS beat(16)134.32%
Revenue beat(2)1
Avg Revenue beat(2)57.05%
Min Revenue beat(2)-52.63%
Max Revenue beat(2)166.72%
Revenue beat(4)2
Avg Revenue beat(4)17.73%
Min Revenue beat(4)-74.1%
Max Revenue beat(4)166.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)58.18%
PT rev (3m)47.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-51.87%
Revenue NY rev (1m)-1.64%
Revenue NY rev (3m)-22.06%
Valuation
Industry RankSector Rank
PE 16.98
Fwd PE N/A
P/S 11.12
P/FCF N/A
P/OCF N/A
P/B 3.4
P/tB 3.4
EV/EBITDA N/A
EPS(TTM)0.51
EY5.89%
EPS(NY)-1.85
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0.78
BVpS2.55
TBVpS2.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.41
Profitability
Industry RankSector Rank
ROA -34.06%
ROE -38.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.25
Quick Ratio 8.25
Altman-Z -3.08
F-Score2
WACC9.22%
ROIC/WACCN/A
Cap/Depr(3y)521.74%
Cap/Depr(5y)N/A
Cap/Sales(3y)9.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.92%
EPS 3Y21.91%
EPS 5YN/A
EPS Q2Q%-43.9%
EPS Next Y-230.15%
EPS Next 2Y-78.85%
EPS Next 3Y-39.17%
EPS Next 5YN/A
Revenue 1Y (TTM)-45.44%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%N/A
Revenue Next Year-90.97%
Revenue Next 2Y-75.39%
Revenue Next 3Y-52.73%
Revenue Next 5Y37.92%
EBIT growth 1Y-19.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.97%
OCF growth 3YN/A
OCF growth 5YN/A

LIPOCINE INC / LPCN FAQ

What is the ChartMill fundamental rating of LIPOCINE INC (LPCN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to LPCN.


What is the valuation status of LIPOCINE INC (LPCN) stock?

ChartMill assigns a valuation rating of 2 / 10 to LIPOCINE INC (LPCN). This can be considered as Overvalued.


What is the profitability of LPCN stock?

LIPOCINE INC (LPCN) has a profitability rating of 1 / 10.


How financially healthy is LIPOCINE INC?

The financial health rating of LIPOCINE INC (LPCN) is 7 / 10.